Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide As a member of the immune checkpoint, PD-1 is acknowledged as a key player in immune regulation and a hot target for cancer immunotherapy. The broad and flat binding interface of PD-1 to PD-L1 poses a challenge to non-antibody inhibitor discovery. In this work, through mirror-image phage display, we developed the first d -miniprotein inhibitor of PD-1/PD-L1 interaction, D PDI-49, with nanomolar affinity to PD-1 and single-digit micromolar EC 50 in a cell-based inhibition assay. The binding mode between D PDI-49 and PD-1 was studied by NMR and MD simulations. For comparison, we screened several commercial and in-house short peptide libraries against synthetic d -PD-1. The failure in identifying a hit structure with inhibition activity using those libraries underpins the superiority of the well-folded miniprotein library in PPI inhibitor development for challenging protein targets.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: